Find the claims clinicians believe and act on
HCP message testing for pharma and biotech brand teams, with the physicians, NPs, PAs and pharmacists your brand plan targets. Only MLR-approved stimuli are shown, every transcript is screened for adverse events and every deliverable is de-identified.
What is message testing with Carevoices?
Message testing with Carevoices shows draft claims, core messages and visual aids to the verified clinicians they target. AI-moderated interviews probe what each message means to them, whether they believe it and whether it would change a treatment conversation. You get de-identified transcripts and message-by-message evidence before the campaign locks.
Why does HCP message testing stall today?
Three things brand and insights teams run into when they test messages with clinicians.
Safety claims prompt adverse-event talk
Ask a clinician whether a safety claim rings true and they often answer with a case they treated. Every one of those mentions has to be caught and reported, in every language, or the study becomes a pharmacovigilance problem.
MLR review gates every stimulus
Claims, detail aids and campaign concepts go through medical, legal and regulatory review before any clinician sees them, and again for each revision. Without a clear record of what fielded, review questions pile up.
Scores say which message won, not why
A rating grid shows message B beat message A. It doesn't show which phrase lost credibility, which data point felt overstated, or what a specialist needs to hear before changing practice.
Message testing built for MLR and PV review
Efficacy and safety messages can surface adverse events. These controls run on every study.
-
Only MLR-approved stimuli
Your medical, legal and regulatory reviewers approve every message, claim and visual aid in the study plan. Interviews show nothing else, and revised messages go through the same approval before the next round.
-
AE screening, 24-hour reports
Every transcript is screened for adverse events, with reports to your drug-safety team within 24 hours and a full reconciliation at study end, in every interview language.
-
AE disclosure in consent
Participant consent includes the adverse-event disclosure the market-research codes require.
-
Your brand stays blinded
Sponsor-blinded by default: participants never learn who commissioned the study. Messages can run unbranded or under a placeholder brand name.
-
De-identified deliverables
Every deliverable is de-identified to the HIPAA Safe Harbor standard, with all 18 identifiers removed. Insights deliverables never include participant identities, and no audio or video is shared by default. Contact details reach the sponsor’s drug-safety team only if the clinician agrees to adverse-event follow-up; any unblinded work is agreed in the study plan.
From draft claims to message-by-message evidence
Send your brief
Share the messages, claims or visual aids and the clinicians they target. The proposal confirms recruitment feasibility for each specialty.
MLR signs off
Your reviewers approve the screener, guide and every stimulus. Nothing fields until they do.
Clinicians respond
Verified clinicians complete AI-moderated voice, video or chat interviews, and each message is probed for clarity, credibility and likely impact on practice.
Evidence delivered
De-identified transcripts and message-by-message evidence land in your research repository, ready for your own analysis tools.
What brand teams test
with Carevoices
Claims and core messages
Test efficacy, safety and mechanism-of-action claims, and the order they appear in, with the specialists who will hear them from a field representative.
Visual aids and campaign concepts
Show detail aids, campaign concepts and digital assets in voice or video interviews, and probe each panel or frame for comprehension and credibility.
Segment-by-segment resonance
Compare how academic and community specialists, primary care, NPs, PAs and pharmacists react to the same message, with the same screening criteria for each segment.
Carevoices vs.
traditional message testing
| Dimension | Carevoices | Rating surveys and focus groups |
|---|---|---|
| Who answers | Every clinician is identity-, license- and NPI-verified before an invitation; roles without an NPI are identity- and license-verified. | Panel respondents, with verification that varies by vendor |
| Depth | Natural conversation with 5–7 levels of laddering on clinical reasoning. | A score per message and short open-ends |
| Safety reporting | Every transcript screened, in every interview language | Varies by vendor, moderator and language |
| Iteration | Refined messages field under the same plan once approved | A new scope and a new recruit for each round |
| Segments | Same screening criteria for every segment, in 80+ languages | Separate recruits, market by market |
Common questions
Launch with messages clinicians already trust
Send a brief and get a proposal within 24 hours. Bring the messages, the audience and any visual aids.
Send a brief and get a scoped pilot proposal with feasibility, timing and price
See a sample de-identified message-testing deliverable and how adverse-event reporting works
Start with a pilot study, quoted from your brief within 24 hours, from $12,000. Then scale with an annual plan sized to the number of interviews you want to complete. Your pilot fee counts toward your first plan.
Go deeper on HCP message testing
Pillar Guides
Deep-dive guides covering this topic from strategy to execution.
Compliance reference guides
Practical frameworks and platform-specific guides for teams ready to act.
Alternatives & Comparisons
Side-by-side comparisons with competing platforms and approaches.
Who it's for
The platform features that power this type of research.